We're Putting (Nasdaq: MDCX) On Our Radar After July FDA Clearance (5 Potential Catalysts)

Just days ago — on July 27th, 2026

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of Medicus Pharma Ltd. We're Putting (Nasdaq: MDCX) On Our Radar After July FDA Clearance (5 Potential Catalysts) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* July 31st Greetings, Friend! Just days ago — on July 27th, 2026 — Medicus Pharma Ltd. (NASDAQ: MDCX) cleared a regulatory threshold worth understanding. The FDA released a "Study May Proceed" letter for SKNJCT-005, authorizing MDCX to launch an NDA-enabling Phase 2b registrational clinical trial of SkinJect® in patients living with Gorlin Syndrome. This clearance marks a definitive transition from exploratory Phase 2 clinical work into registrational-grade development. Gorlin Syndrome — additionally known as Nevoid Basal Cell Carcinoma Syndrome — is a rare genetic disorder that subjects patients to an unrelenting cycle of surgical procedures across their lifetime. Individuals with the condition can develop dozens to more than 1,000 basal cell carcinoma lesions, with onset often occurring as early as childhood or adolescence. No FDA-approved lesion-directed treatment currently exists for this patient population. That is the clinical void SkinJect is built to address. The product is a dissolvable microneedle array patch engineered to deliver doxorubicin chemotherapy directly and precisely into basal cell carcinoma tumors. Results from prior Phase 2 study SKNJCT-003 — which enrolled 90 patients across nine U.S. sites — showed 64% clinical clearance and 55% histological clearance at Day 57 in the 200 mcg dose group, with no treatment-related serious adverse events reported. The study established a clear dose-response relationship, generating what the company has called "decision-grade" evidence. Under SKNJCT-005, up to 50 Gorlin Syndrome patients will be enrolled, with the protocol targeting two to four lesions simultaneously. The FDA's requirement of at least two years of extended patient follow-up is something management has characterized as a protocol enhancement reinforcing durability evaluation — not a limiting condition. Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, called the FDA's action "a significant regulatory milestone." Alongside SkinJect, MDCX is actively advancing Teverelix — a long-acting injectable GnRH antagonist developed for advanced prostate cancer patients carrying elevated cardiovascular risk. The FDA issued a "Study May Proceed" authorization for a Teverelix Phase 2b dose-optimization study in February 2026, and the company has filed a substantial modification application through the EU Clinical Trials Information System targeting European clinical expansion. Taken together, the two programs address an estimated $8Bn in addressable markets across multiple indications. Breaking Down The Company: Medicus Pharma Ltd. Medicus Pharma Ltd. is a precision-medicine-focused biotech with a presence across three continents. Its foundational model is a "de-risk and partner" approach: push novel therapeutic assets through Phase 2 proof-of-concept studies, then engage established pharmaceutical partners for licensing or commercialization agreements. The company joined Nasdaq in January 2025 and celebrated its first year on the exchange with a bell-ringing ceremony on January 22nd, 2026. SkinJect (D-MNA) — its lead asset — progresses under the FDA's 505(b)(2) regulatory pathway, allowing the company to draw on the established doxorubicin safety record and potentially shorten the regulatory review cycle. Teverelix was added to the pipeline through the August 2025 acquisition of UK-headquartered Antev Ltd., expanding MDCX's clinical reach into advanced prostate cancer in men with high cardiovascular risk. Phase 1 data on Teverelix presented at AACE 2026 confirmed predictable, dose-dependent hormone suppression with no unexpected safety signals. Active collaborations include a working relationship with Reliant AI Inc. on clinical analytics and a memorandum of understanding with Helix Nanotechnologies targeting mRNA vaccine applications. (Nasdaq: MDCX) Has 5 Key Potential Catalysts We're Currently Tracking 1). FDA Study May Proceed Letter Puts MDCX On The Registrational Track. The July 27th, 2026 clearance for SKNJCT-005 positions MDCX as the only company currently advancing a lesion-directed therapy toward an NDA specifically for Gorlin Syndrome — a condition with no FDA-approved lesion-directed treatment today. 2). Orphan Drug Status Application Seeks Seven Years Of Potential Exclusivity. MDCX submitted an Orphan Drug Designation application in April 2026 for SkinJect in Gorlin Syndrome, which — if granted — would provide MDCX a potential NDA fee exemption exceeding $5Mn and seven years of market exclusivity from the date of FDA approval. 3). Rare Pediatric Disease Designation Request Could Produce A Priority Review Voucher. Filed in June 2026, the Rare Pediatric Disease Designation request for SkinJect — if awarded — would make MDCX eligible to receive a Priority Review Voucher upon NDA approval, a regulatory instrument with established value in the pharmaceutical licensing market. 4). Dual-Market Regulatory Push Positions Teverelix In The U.S. And Europe. Having received FDA Phase 2b clearance in February 2026 and submitted for EU clinical expansion through the CTIS platform, MDCX is simultaneously progressing Teverelix across two of the world's largest pharmaceutical markets — targeting a combined addressable market the company pegs at approximately $6Bn. 5). 505(b)(2) Strategy Leverages Existing Doxorubicin Data To Streamline Review. The FDA's confirmation that SkinJect qualifies for the 505(b)(2) pathway permits MDCX to integrate existing doxorubicin safety information into its NDA submission, a strategic filing advantage that could reduce both regulatory cost and time-to-decision compared to a new chemical entity submission. Closing Thoughts Medicus Pharma Ltd. (Nasdaq: MDCX) has not been generating attention without substance behind it. The announcements this company has made over the past 18 months have consistently carried regulatory or clinical significance: Phase 2 data, FDA clearances, designation applications, conference presentations, and now formal clearance to begin a registrational trial for a rare disease where no approved lesion-directed therapy exists. That is a pattern worth noting. If you're tracking the biotech space for names with concrete near-term milestones and a pipeline built on clinical evidence first, MDCX belongs on your radar as 2026 continues to take shape. We're initiating coverage on Medicus Pharma Ltd. (Nasdaq: MDCX). Updates are coming — watch for them. Talk soon. All the best, Dane James Editor Market Pulse Today Additional Source: MDCX Website (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice